Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-16T14:52:00.542Z Has data issue: false hasContentIssue false
  • English
  • Français

Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms

Published online by Cambridge University Press:  07 November 2014

Daniel E. Casey
Daniel E. Casey*
Affiliation:
Dr. Casey is a professor in the Departments of Psychiatry and Neurology at the Oregon Health &, Science University in Portland
*
Daniel E. Casey, MD, Oregon Health &, Science University, UHN80 Department of Psychiatry, 3181 S.W. Sam Jackson Park Rd, Portland, OR 97239; Tel: 503-418-1291; Fax:, 503-418-1294; E-mail:, caseyd@ohsu.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Development of extrapyramidal symptoms (EPS), particularly tardive dyskinesia (TD), has long been a troubling side effect for patients taking antipsychotics. Atypical antipsychotics have been hailed as an improvement over conventional antipsychotics, offering similar efficacy with more favorable EPS profiles. In the recent Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, which compared the conventional antipsychotic perphenazine with atypical antipsychotics olanzapine, quetiapine, risperidone, and ziprasidone in patients with schizophrenia, no significant differences in time to treatment discontinuation due to intolerability were observed between treatment groups. However, perphenazine was associated with a higher rate of patients experiencing EPS as well as a significantly higher rate of discontinuation due to EPS, despite the fact that patients with TD at baseline were excluded from the perphenazine group. Unfortunately, due to short treatment duration, the CATIE study did not have the assay sensitivity to detect differences in TD risk among any of the drugs. Thus, the atypical antipsychotics remain the first line of treatment for most patients, with specific drug selection based on benefit-risk profiles that best fit the individual patient's needs. Frequent monitoring, while noting a patient's subjective experience, remains the best strategy for choosing therapy to maximize symptom relief and minimize the impact of EPS and other side effects over the long-term. This article explores the reported results of the CATIE trial regarding EPS and emphasizes the differentiation of the atypicals from perphenazine on EPS and how these results should be incorporated into daily practice for the clinician.

Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S7 , 2006 , pp. 25 - 31
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Casey, DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol. 1995;10:105–114.Google ScholarPubMed
2.Casey, DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35:S61–S66.CrossRefGoogle ScholarPubMed
3.Casey, DE. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol. 1997;12:S19–S27.CrossRefGoogle ScholarPubMed
4.Pierre, JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention, and management. Drug Saf. 2005;28:191–208.CrossRefGoogle ScholarPubMed
5.National Institute of Mental Health. CGI: Clinical Global Impressions. In: Guy, W, Bonato, RR, eds. Manual for the ECDEU Assessment Battery. 2. Rev ed. Chevy Chase, Md: National Institute of Mental Health; 1970:12–16.Google Scholar
6.Tandon, R. Safety and tolerability: How do newer generation “atypical” antipsychotics compare? Psychiatr Q. 2002;73(4):297–311.CrossRefGoogle ScholarPubMed
7.Kerwin, RW. The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994;164:141–148.CrossRefGoogle ScholarPubMed
8.Geddes, J, Freemantle, N, Harrison, P, Bebbington, P, for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta regression analysis. BMJ. 2000;321:1371–1376.CrossRefGoogle Scholar
9.Lieberman, JA, Stroup, TS, McEvoy, JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N Engl J Med. 2005;353:1209–1223.CrossRefGoogle Scholar
10. IMS Health. Atypical antipsychotics: generating evidence to inform policy and practice. Available at: http://research.imshealth.com/research_schizophrenia.htm. Accessed February 14, 2006.Google Scholar
11.Harrington, C, Gregorian, R, Gemmen, E, et al. The Lewin Group. Access and utilization of new antidepressant and antipsychotic medications. Falls Church, Va: The Office of the Assistant Secretary for Planning and Evaluation, the National Institute of Mental Health, US Dept. of Health and Human Services; 2000. Available at: http://aspe.hhs.gov/health/reports/Psychmedaccess/. Accessed: February 13, 2006.Google Scholar
12.Geddes, J. Generalizing evidence to inform policy and practice: the example of the second generation “atypical” antipsychotics. Schizophr Bull. 2003;29:105–114.CrossRefGoogle ScholarPubMed
13.Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68.CrossRefGoogle ScholarPubMed
14.Wahlbeck, K, Tuunainen, A, Ahokas, A, Leucht, S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230–233.CrossRefGoogle ScholarPubMed
15.Davis, JM, Chen, N, Glick, ID. A metaanalysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553–564.CrossRefGoogle ScholarPubMed
16.Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–1589.CrossRefGoogle ScholarPubMed
17.Leucht, S, Barnes, TRE, Kissling, W, Engel, RR, Correll, C, Kane, JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209–1222.CrossRefGoogle ScholarPubMed
18.Stroup, TS, McEvoy, JP, Swartz, MS, et al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia design and protocol development. Schizophr Bull. 2003;29:15–31.CrossRefGoogle ScholarPubMed
19.Kulkarni, SK, Naidu, PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003;39:19–49.CrossRefGoogle ScholarPubMed
20.Brown, KW, White, T. Sub-syndromes of tardive dyskinesia and some clinical correlates. Psychol Med. 1992;22:923–927.CrossRefGoogle ScholarPubMed
21.Miller, DD, McEvoy, JP, Davis, SM, et al.Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33–43.CrossRefGoogle ScholarPubMed
22.Llorca, P-M, Chereau, I, Bayle, F-J, Lancon, C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry. 2002;17:129–138.CrossRefGoogle ScholarPubMed
23.Glazer, WM. Review of incidence studies of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61:15–20.Google ScholarPubMed
24.Sweet, RA, Mulsant, BH, Gupta, B, et al.Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry. 1995;52:478–486.CrossRefGoogle ScholarPubMed
25.Woerner, MG, Alvir, JMJ, Saltz, BL, Lieberman, JA, Kane, JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521–1528.CrossRefGoogle ScholarPubMed
26.Dixon, L, Weiden, PJ, Haas, G, Sweeney, J, Frances, AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry. 1992;33:121–122.CrossRefGoogle ScholarPubMed
27.Olivera, AA, Kiefer, MW, Manley, NK. Tardive dyskinesia in psychiatric patients with substance abuse disorders. Am J Drug Alcohol Abuse. 1990;16:57–66.Google Scholar
28.Jeste, DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61:27–32.Google ScholarPubMed
29.Yassa, R, Jeste, DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701–715.CrossRefGoogle ScholarPubMed
30.Levy, E, Margolese, HC, Annable, L, Chouinard, G. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use. Can J Psychiatry. 2004;49:398–402.CrossRefGoogle ScholarPubMed
31.Ganzini, L, Heintz, RT, Hoffman, WF, Casey, DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry. 1991;48:259–263.CrossRefGoogle ScholarPubMed
32.Woerner, MG, Saltz, BL, Kane, JM, Lieberman, JA, Alvir, JM. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966–968.Google ScholarPubMed
33.Schooler, NR, Kane, JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.Google ScholarPubMed
34.Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.CrossRefGoogle ScholarPubMed
35.Barnes, TR. The Barnes Akathisia Rating Scale--revisited. J Psychopharmacol. 2003;17(4):365–370.CrossRefGoogle ScholarPubMed
36.Lehman, AF, Lieberman, JA, Dixon, LB, et al.American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 Feb;161:1–56.Google Scholar